KCL in D5W
"As required by the bipartisan FDA Food Safety Modernization Act (FSMA), the U.S. Food and Drug Administration today proposed a rule that would require the largest food businesses in the United States and abroad to take steps to prevent facilities"...
KCL in D5W
KCL in D5W Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
KCL in D5W (potassium chloride in 5% dextrose injection) is a fluid and electrolyte replenishment and caloric supply, used as a source of water, electrolytes and calories. Common side effects of KCL in D5W include fever, nausea, vomiting, abdominal pain, diarrhea, and infection, redness, pain, or swelling at the injection site.
Dosage of KCL in D5W is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. KCL in D5W may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, KCL in D5W should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our KCL in D5W (potassium chloride in 5% dextrose injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
KCL in D5W FDA Prescribing Information: Side Effects
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
Reactions reported with the use of potassium-containing solutions include nausea, vomiting, abdominal pain and diarrhea. The signs and symptoms of potassium intoxication include paresthesias of the extremities, areflexia, muscular or respiratory paralysis, mental confusion, weakness, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities and cardiac arrest. Potassium deficits result in disruption of neuromuscular function, and intestinal ileus and dilatation.
Dextrose may be administered at a rate of 0.5 g/kg/hour without producing glycosuria. Hyperglycemia and glycosuria may be a function of rate of administration or metabolic insufficiency. Appropriate therapy may include slowing of the infusion rate and administration of insulin.
The physician should also be alert to the possibility of adverse reactions to drug additives. Prescribing information for drug additives to be administered in this manner should be consulted.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Read the entire FDA prescribing information for KCL in D5W (Potassium Chloride in 5% Dextrose Injection)
Additional KCL in D5W Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Weight Loss Wisdom
Get tips, recipes and inspiration.